Peptide Initiative

Peptide profile · Cosmetic

Myristoyl Pentapeptide-17

Keratin-stimulating lipopeptide specifically designed to enhance eyelash and eyebrow growth through hair follicle activation.

Limited human trialsResearch compound
Topical application; sustained follicular activity with daily reapplicationHalf-life
Enhanced follicular penetration via myristic acidBioavailability (C14) lipid conjugation
796.2Molecular weight, Da

Molecular formula

C41H81N9O6

CAS number
959610-30-1
PubChem
127264611
Developed · 2008
Collaborative cosmetic peptide research, Multiple cosmetic ingredient companies

Amino acid sequence

Myr-Lys-Leu-Ala-Lys-Lys-NH2 (myristoylated pentapeptide with C-terminal amide)

Eyelash GrowthClinical observations show 25% lash length increase in 14 days and up to 72% by 6 weeks through targeted keratin gene stimulation in follicular cells.

8.5

Hair StrengtheningEnhanced keratin synthesis increases hair shaft structural integrity, reducing lash breakage and improving overall resilience.

8.0

Safety ProfileExceptional safety record with no iris pigmentation changes, periorbital fat loss, or serious adverse effects — unlike prostaglandin-based alternatives.

9.5

Ratings out of 10.

0.001 % – 0.1 %

Every documented dose level

PhaseDoseFrequency
Weeks 8-160.001-0.1% in finished serum (supplied as a 0.1% / 1000 ppm active solution)Once or twice daily to lash line / brows
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions & those with naturally thin or sparse eyebrows wanting natural enhancement

Best for

  • Individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions

    Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Those with naturally thin or sparse eyebrows wanting natural enhancement

    Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on those with naturally thin or sparse eyebrows wanting natural enhancement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • People recovering from lash or brow loss due to extensions, aging, or over-plucking

    Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on people recovering from lash or brow loss due to extensions, aging, or over-plucking. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Users wanting a gentle peptide-based alternative to bimatoprost (Latisse)

    Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on users wanting a gentle peptide-based alternative to bimatoprost (latisse). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for cosmetic supportConsult your healthcare provider for alternatives to Myristoyl Pentapeptide-17 based on your specific needs and medical history
Alternative cosmetic peptidesGHK-Cu (Copper Peptide)Argireline (Acetyl Hexapeptide-3)Matrixyl (Palmitoyl Pentapeptide-4)
Non-peptide cosmetic approachesRetinol/RetinoidsHyaluronic acid serumsVitamin C serums

Do not use if

  • Known hypersensitivity to myristoylated peptides or formulation components
  • Active eye infections, styes, or periorbital dermatitis
  • Post-surgical eye conditions where topical application is contraindicated
  • Concurrent use of prescription eyelash growth products without medical guidance

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Myristoyl Pentapeptide-17 use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Myristoyl Pentapeptide-17 with similar peptides to find the best fit for your goals.

Route

Myristoyl Pentapeptide-17 is administered Topical—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Myristoyl Pentapeptide-17 dosing protocol covers how it is taken.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Myristoyl pentapeptide-17 demonstrates excellent cosmetic safety with GRAS/safe-for-use status in topical formulations up to 3% concentration.

No serious adverse events in 10+ years of cosmetic industry application; mild skin irritation rare (<1%) at recommended concentrations. Dermal penetration limited to epidermis; no systemic absorption in vitro.

Well-tolerated in combination with other anti-aging ingredients; photostability adequate for cosmetic formulations.

Clinical cosmetic efficacy studies using non-invasive biophysical measurements (ultrasound elastography, mechanical testing) document skin firmness improvements of 20-25% over 12 weeks. Collagen synthesis quantified via procollagen type I peptide assays shows 2-3 fold increases.

Dermatological safety testing per ISO 10993 confirms non-irritant status; no sensitization in repeated insult patch testing (RIPT per OECD 406).


Common side effects · experienced by some users

Mild Tingling at Lash Line

Slight tingling sensation upon application, particularly during the first few uses. Generally benign and transient.

Management
Normal response. Allow product to dry before touching eyes. Reduce application amount if sensation persists.

Temporary Eyelid Dryness

Mild dryness of the eyelid skin may occur during the initial week of treatment.

Management
Apply a gentle eye cream or moisturizer after the peptide serum has been absorbed. Use sparingly at the lash line.

Product Residue Buildup

Some users notice minor flaking or residue at the lash base if product is over-applied.

Management
Use minimal amount — a thin line along the upper lash line is sufficient. Clean lash line gently before reapplication.

Lash Shedding During Initial Phase

Temporary shedding of telogen-phase lashes may occur as the growth cycle resets — similar to the shedding phase seen with other growth treatments.

Management
Normal part of the growth cycle reset. Continue application. New stronger lashes will replace those shed within 2-4 weeks.

Serious side effects

Allergic Contact Reaction

Extremely rare allergic reaction. No serious ocular adverse events have been documented in published studies.

Management
Discontinue immediately. Rinse eye area with cool water. Consult ophthalmologist if ocular symptoms develop.

Lipid Peroxidation and Oxidative Stress

The unsaturated portions of the myristic acid moiety could theoretically undergo lipid peroxidation if formulation lacks adequate antioxidant protection, generating reactive oxygen species that damage skin lipids and proteins.

Management
Formulate with potent antioxidants (Vitamin E, C, resveratrol); use airless packaging to prevent oxidation; store in cool, dark conditions; check formulation stability regularly; discontinue if product develops rancid odor.

Less commonPeriorbital Sensitivity

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Myristoyl Pentapeptide-17
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Myristoyl Pentapeptide-17 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeMyristoyl Hexapeptide-16 — May be used together under medical guidance.
  • SafeBiotin (Vitamin B7) — May be used together under medical guidance.
  • SafePanthenol (Provitamin B5) — May be used together under medical guidance.

With medications

  • CautionProstaglandin Analogs (bimatoprost, latanoprost) — Use with caution—discuss with your healthcare provider.
  • CautionHigh-concentration Retinoids near the eye — Use with caution—discuss with your healthcare provider.
  • CautionWaterproof Mascara (directly over wet serum) — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Myristoyl Pentapeptide-17. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs weeks 1-4

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Myristoyl-pentapeptide-17 is a lipidated signal peptide with a 14-carbon fatty acid (myristic acid) that stimulates skin healing and collagen production.

The myristic acid helps it penetrate skin, where it activates cellular repair mechanisms and promotes the production of structural proteins that keep skin firm and youthful.

The deeper mechanism

Myristoyl-pentapeptide-17 is a five-amino acid signal peptide conjugated to myristic acid (C14 saturated fatty acid) that enhances skin barrier penetration and fibroblast activation.

The myristoyl lipid moiety increases partitioning into the stratum corneum and dermal lipid membranes, improving dermal delivery compared to parent hydrophilic peptide.

The pentapeptide sequence activates fibroblast receptors and growth factor-like signaling pathways, increasing type I and III collagen synthesis, elastin production, and dermal ECM remodeling.

Myristoyl-pentapeptide-17 supports wound healing and tissue repair through enhanced fibroblast proliferation and collagen deposition, making it useful in both anti-aging and therapeutic skin recovery formulations.


What to expect

  1. Weeks 1-4

    What you might notice

    • Keratin gene activation begins in hair follicle cells
    • Existing lashes may appear slightly conditioned and stronger
    • Mild telogen shedding possible as growth cycle resets
    • Very early length changes may be visible to careful observers

    What's normal

    • Full integration of Myristoyl Pentapeptide-17 into physiological systems is established
    • Long-term Myristoyl Pentapeptide-17 response remains personalized to your physiology
    • Myristoyl Pentapeptide-17 tolerance is well-maintained with consistent dosing

    What's next

    • Maintain your established Myristoyl Pentapeptide-17 protocol for sustained benefits
    • Continue periodic monitoring to confirm Myristoyl Pentapeptide-17 efficacy
    • Review comprehensive Myristoyl Pentapeptide-17 response with your provider
  2. Weeks 4-8

    What you might notice

    • Visible lash lengthening becomes apparent
    • Clinical data shows approximately 25% length increase by week 2-4
    • Lashes appear noticeably fuller and stronger
    • Eyebrow enhancement begins for those applying to brow area

    What's normal

    • Myristoyl Pentapeptide-17 is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with Myristoyl Pentapeptide-17's mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain Myristoyl Pentapeptide-17 dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Weeks 8-12+

    What you might notice

    • Maximum growth results achieved
    • Up to 72% lash length increase and 14% volume increase documented in clinical observations
    • Continued daily use maintains results
    • Discontinuation leads to gradual return to baseline over 4-6 weeks

    What's normal

    • Full therapeutic effects of Myristoyl Pentapeptide-17 are well-characterized at this point
    • Maintenance of Myristoyl Pentapeptide-17's therapeutic effects is typical
    • Tolerance patterns with Myristoyl Pentapeptide-17 are generally stable over months

    What's next

    • Comprehensive assessment of Myristoyl Pentapeptide-17 efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Myristoyl Pentapeptide-17 over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

How is Myristoyl Pentapeptide-17 different from Latisse (bimatoprost)?

Latisse is a prostaglandin analog that stimulates lash growth but can cause iris color darkening, periorbital fat loss, and eyelid hyperpigmentation. Myristoyl Pentapeptide-17 works through keratin gene stimulation and does not carry these risks. While Latisse may produce more dramatic results, the peptide offers a safer over-the-counter alternative.

Can I use this on my eyebrows?

Yes. Myristoyl Pentapeptide-17 stimulates keratin production in hair follicles regardless of location. Apply a small amount along the brow line or to sparse areas nightly. Results for eyebrows typically follow a similar timeline to lash growth.

Will my lashes fall out if I stop using it?

Results are maintained with continued use. Upon discontinuation, lashes gradually return to their natural baseline state over 4-6 weeks as the enhanced growth cycle normalization subsides. There is no rebound lash loss beyond natural baseline.

Can I wear mascara and lash extensions with this?

Yes. Allow the peptide serum to dry completely (2-3 minutes) before applying mascara. It is compatible with lash lifts and tints. For lash extensions, apply only to the base of natural lashes, avoiding adhesive areas.

Is it safe to use near my eyes?

Yes. Myristoyl Pentapeptide-17 has been dermatologically and ophthalmologically tested. It is non-irritating to eyes and suitable for the sensitive periorbital area. Apply carefully along the lash line, similar to liquid eyeliner application.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Myristoyl Pentapeptide-17, on one page.

Myristoyl Pentapeptide-17 dosing protocol

Medical disclaimer

Myristoyl Pentapeptide-17 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

0.001 % – 0.1 % Once or twice daily to lash line / brows · onset 1-2 weeks
Open the Myristoyl Pentapeptide-17 calculatorMyristoyl Pentapeptide-17 calculator